Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine
-
- Chantal Pauli
- 1Englander Institute for Precision Medicine, Weill Cornell Medicine-New York Presbyterian Hospital, New York, New York.
-
- Benjamin D. Hopkins
- 4Meyer Cancer Center, Weill Cornell Medicine, New York, New York.
-
- Davide Prandi
- 5Center for Integrative Biology, University of Trento, Trento, Italy.
-
- Reid Shaw
- 6Cure First and SEngine Precision Medicine, Seattle, Washington.
-
- Tarcisio Fedrizzi
- 5Center for Integrative Biology, University of Trento, Trento, Italy.
-
- Andrea Sboner
- 1Englander Institute for Precision Medicine, Weill Cornell Medicine-New York Presbyterian Hospital, New York, New York.
-
- Verena Sailer
- 1Englander Institute for Precision Medicine, Weill Cornell Medicine-New York Presbyterian Hospital, New York, New York.
-
- Michael Augello
- 1Englander Institute for Precision Medicine, Weill Cornell Medicine-New York Presbyterian Hospital, New York, New York.
-
- Loredana Puca
- 1Englander Institute for Precision Medicine, Weill Cornell Medicine-New York Presbyterian Hospital, New York, New York.
-
- Rachele Rosati
- 6Cure First and SEngine Precision Medicine, Seattle, Washington.
-
- Terra J. McNary
- 1Englander Institute for Precision Medicine, Weill Cornell Medicine-New York Presbyterian Hospital, New York, New York.
-
- Yelena Churakova
- 1Englander Institute for Precision Medicine, Weill Cornell Medicine-New York Presbyterian Hospital, New York, New York.
-
- Cynthia Cheung
- 1Englander Institute for Precision Medicine, Weill Cornell Medicine-New York Presbyterian Hospital, New York, New York.
-
- Joanna Triscott
- 1Englander Institute for Precision Medicine, Weill Cornell Medicine-New York Presbyterian Hospital, New York, New York.
-
- David Pisapia
- 1Englander Institute for Precision Medicine, Weill Cornell Medicine-New York Presbyterian Hospital, New York, New York.
-
- Rema Rao
- 1Englander Institute for Precision Medicine, Weill Cornell Medicine-New York Presbyterian Hospital, New York, New York.
-
- Juan Miguel Mosquera
- 1Englander Institute for Precision Medicine, Weill Cornell Medicine-New York Presbyterian Hospital, New York, New York.
-
- Brian Robinson
- 1Englander Institute for Precision Medicine, Weill Cornell Medicine-New York Presbyterian Hospital, New York, New York.
-
- Bishoy M. Faltas
- 1Englander Institute for Precision Medicine, Weill Cornell Medicine-New York Presbyterian Hospital, New York, New York.
-
- Brooke E. Emerling
- 4Meyer Cancer Center, Weill Cornell Medicine, New York, New York.
-
- Vijayakrishna K. Gadi
- 9Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
-
- Brady Bernard
- 6Cure First and SEngine Precision Medicine, Seattle, Washington.
-
- Olivier Elemento
- 1Englander Institute for Precision Medicine, Weill Cornell Medicine-New York Presbyterian Hospital, New York, New York.
-
- Himisha Beltran
- 1Englander Institute for Precision Medicine, Weill Cornell Medicine-New York Presbyterian Hospital, New York, New York.
-
- Francesca Demichelis
- 1Englander Institute for Precision Medicine, Weill Cornell Medicine-New York Presbyterian Hospital, New York, New York.
-
- Christopher J. Kemp
- 10Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington.
-
- Carla Grandori
- 6Cure First and SEngine Precision Medicine, Seattle, Washington.
-
- Lewis C. Cantley
- 4Meyer Cancer Center, Weill Cornell Medicine, New York, New York.
-
- Mark A. Rubin
- 1Englander Institute for Precision Medicine, Weill Cornell Medicine-New York Presbyterian Hospital, New York, New York.
Description
<jats:title>Abstract</jats:title> <jats:p>Precision medicine is an approach that takes into account the influence of individuals' genes, environment, and lifestyle exposures to tailor interventions. Here, we describe the development of a robust precision cancer care platform that integrates whole-exome sequencing with a living biobank that enables high-throughput drug screens on patient-derived tumor organoids. To date, 56 tumor-derived organoid cultures and 19 patient-derived xenograft (PDX) models have been established from the 769 patients enrolled in an Institutional Review Board–approved clinical trial. Because genomics alone was insufficient to identify therapeutic options for the majority of patients with advanced disease, we used high-throughput drug screening to discover effective treatment strategies. Analysis of tumor-derived cells from four cases, two uterine malignancies and two colon cancers, identified effective drugs and drug combinations that were subsequently validated using 3-D cultures and PDX models. This platform thereby promotes the discovery of novel therapeutic approaches that can be assessed in clinical trials and provides personalized therapeutic options for individual patients where standard clinical options have been exhausted.</jats:p> <jats:p>Significance: Integration of genomic data with drug screening from personalized in vitro and in vivo cancer models guides precision cancer care and fuels next-generation research. Cancer Discov; 7(5); 462–77. ©2017 AACR.</jats:p> <jats:p>See related commentary by Picco and Garnett, p. 456.</jats:p> <jats:p>This article is highlighted in the In This Issue feature, p. 443</jats:p>
Journal
-
- Cancer Discovery
-
Cancer Discovery 7 (5), 462-477, 2017-04-30
American Association for Cancer Research (AACR)
- Tweet
Details 詳細情報について
-
- CRID
- 1363388845024123904
-
- ISSN
- 21598290
- 21598274
-
- Data Source
-
- Crossref